Form 4: Immunome Director Philip Wagenheim Receives New Stock Option Grant

Immunome Inc. Director Philip Wagenheim was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year.

Summary

• Immunome Inc. (IMNM) Director Philip Wagenheim was granted 18,864 Director Stock Options.
• The options have an exercise price of $9.57 per share.
• The transaction date for this grant was June 10, 2025.
• The options will vest in four equal quarterly installments, commencing from June 10, 2025, until the one-year anniversary thereafter.
• Vesting is contingent upon Mr. Wagenheim's continuous service with the company on each respective vesting date.
• The expiration date for these options is June 9, 2035.
• Following this transaction, Mr. Wagenheim beneficially owns 18,864 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (stock option grant) for a director, which is generally viewed as neutral to slightly positive as it aligns management interests with shareholders. There are no negative financial or operational disclosures.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term performance and value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Risks

• The vesting of the stock options is subject to the reporting person's continuous service with the company, meaning the options could be forfeited if service is terminated before full vesting.

Future Outlook

The vesting schedule indicates that the director's equity stake will increase over the next year, contingent on their continued service, which suggests an expectation of ongoing commitment from the director to the company's performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options is a standard form of equity compensation for directors in the biotech sector, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) which also utilize equity incentives to align director interests with company performance.
• The vesting schedule of quarterly installments over one year is a common structure for director option grants, similar to those observed at various small to mid-cap biotech firms, ensuring continued engagement.

Corporate Governance

Related Party Transactions

• The grant of stock options to Philip Wagenheim, a director of Immunome Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The options will continue to vest in quarterly installments over the next year, subject to the director's continuous service.

Key Dates

Keywords

Immunome, IMNM, Stock Option, Director Compensation, Executive Compensation, SEC Form 4, Equity Grant, Insider Transaction, Biotechnology